PyInvesting

Market research

HQL Tekla Life Sciences Investors

NYSE USD Financial Services

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
650M
P/E ratio
3.37
Analyst target
Not available
Dividend yield
8.6%
Beta
0.71

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

Tekla Life Sciences Investors is currently in a long term uptrend where the price is trading 6.7% above its 200 day moving average.

From a valuation standpoint, the stock is 57.0% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 3.9.

Tekla Life Sciences Investors's total revenue rose by 65.9% to $2M since the same quarter in the previous year.

Its net income has increased by 196.2% to $30M since the same quarter in the previous year.

Based on the above factors, Tekla Life Sciences Investors gets an overall score of 4/5.